Bioline Rx reported $-554K in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Arca Biopharma USD -25.07M 5.23M Mar/2025
Bio Path USD -3.21M 631K Mar/2025
Bioline Rx USD -554K 2.93M Sep/2025
Capricor Therapeutics USD -24.58M 17.26M Mar/2025